Indications
Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Composition
- Active substance
- tobramycin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vantobra
- Active substance
- tobramycin
- ATC code
- J01GB01
- Therapeutic area
- Cystic Fibrosis, Respiratory Tract Infections
- Marketing authorisation holder
- Pari Pharma GmbH
- Status